Mouse models of acute promyelocytic leukemia

Current Opinion in Hematology

Volumn 8, Issue 4, 2001, Pages 206-211

  Pollock, Jessica L ^a   Westervelt, Peter ^a   Walter, Matthew J ^a   Lane, Andrew A ^a   Ley, Timothy J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; FLT3 LIGAND; HYBRID PROTEIN; NUCLEAR PROTEIN; NUCLEOPHOSMIN; PROTEIN BCL 2; RETINOIC ACID; RETINOIC ACID RECEPTOR; STAT5B PROTEIN; ZINC FINGER PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; CHROMOSOME DELETION; CHROMOSOME DELETION 2; GENE MUTATION; GENE TRANSLOCATION; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENIC; CHROMOSOME DELETION; DISEASE MODELS, ANIMAL; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MODELS, BIOLOGICAL; MUTATION; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; TRETINOIN;

EID: 0034891006     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200107000-00005     Document Type: Review

References (62)

1. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
2. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
3. Cytogenetic studies in acute promyelocytic leukemia: A survey of secondary chromosomal abnormalities
4. Secondary chromosomal abnormalities in acute leukemias
5. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: Cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial
6. Secondary cytogenetic changes in acute promyelocytic leukemia-prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: A cancer and leukemia group B study
7. Early myeloid-specific expression of the human cathepsin G gene in transgenic mice
8. Altered myeloid development and acute leukemia in transgenic mice expressing PML/RARα under control of cathepsin G regulatory sequences
9. Acute leukemia with promyelocytic features in PML-RARα transgenic mice
10. A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia
11. Immunophenotype of adult and childhood acute promyelocytic leukaemia: Correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases
12. Evidence for early hematopoietic progenitor cell involvement in acute promyelocytic leukemia
13. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARα gene rearrangements
14. A PMLRARα transgene initiates murine acute promyelocytic leukemia
15. Distinct interactions of PML-RARα and PLZF-RARα with co-repressers determine differential responses to RA in APL
16. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARα and NPM-RARα
17. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion
18. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins
19. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
20. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
21. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins
22. 3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice
23. Molecular remissions induced with liposomal ATRA (ATRAGEN) in a transgenic murine acute promyelocytic leukemia (APL) model
24. Overexpression of wild-type retinoic acid receptor α (RARα) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARα-fusion genes
25. Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development
26. Leukemia initiated by PMLRARα: The PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable
27. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation
28. Role of promyelocytic leukemia (PML) protein in tumor suppression
29. Role of PML in cell growth and the retinoic acid pathway
30. Retinoid receptors and acute promyelocytic leukaemia
31. Normal development and growth of mice carrying a targeted disruption of the α1 retinoic acid receptor gene
32. High postnatal lethality and testis degeneration in retinoic acid receptor α mutant mice
33. Targeted disruption of retinoic acid receptor α (PARα) and RARα results in receptor-specific alterations in retinoic acid-mediated differentiation and retinoic acid metabolism
34. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptor α1 and γ
35. Positive and negative regulation of granulopoiesis by endogenous RARα
36. Vitamin A deficiency in mice causes a systemic expansion of myeloid cells
37. Expression pattern of the RARα-PML fusion gene in acute promyelocytic leukemia
38. Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-α chimera generated in t(11;17)-associated acute promyelocytic leukemia
39. Diagnosis of acute promyelocytic leukaemia by RT-PCR: Detection of PML-RARA and RARA-PML fusion transcripts
40. Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein
41. RARα1/RARα2-PML mRNA expression in acute promyelocytic leukemia cells: A molecular and laboratory-clinical correlative study
42. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia
43. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): A report on 50 patients
44. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia
45. Two critical hits for promyelocytic leukemia
46. Chromosomal aberrations observed in 52 mouse myeloid leukemias
47. Chromosome mapping of the genes that control differentiation and malignancy in myeloid leukemic cells
48. Myeloid leukaemia in X-ray irradiated CBA mice
49. High incidence of acute myeloid leukemia in SJL/J mice after X-irradiation and corticosteroids
50. Radiation-induced myeloid leukemia in C3H/He mice and the effect of prednisolone acetate on leukemogenesis
51. Molecular mapping of chromosome 2 deletions in murine radiation-induced AML localizes a putative tumor suppressor gene to a 1.0 cM region homologous to human chromosome segment 11p11-12
52. Somatic cell hybrids for high-density mapping of chromosome 2 breakpoints in radiation-induced myeloid leukemia cell lines from inbred mice
53. Characterization of genetic instability in radiation- and benzene-induced murine acute leukemia
54. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice
55. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor α chimeric protein (PMLRARα) to block neutrophil differentiation and initiate acute leukemia
56. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
57. Acute myeloid leukemia
58. Bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages
59. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family
60. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations
61. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
62. FLT3 length mutations in AML: Correlation to cytogenetics, FAB subtype and prognosis in 652 patients